Published in Lancet on March 19, 1988
The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med (1994) 5.55
Significance of systemic endotoxaemia in inflammatory bowel disease. Gut (1995) 2.21
Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun (1996) 2.13
Septin: a factor in plasma that opsonizes lipopolysaccharide-bearing particles for recognition by CD14 on phagocytes. J Exp Med (1992) 1.85
Endotoxemia: methods of detection and clinical correlates. Clin Microbiol Rev (1995) 1.73
Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care (2002) 1.61
Choice of bacteria in animal models of sepsis. Infect Immun (1993) 1.51
A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect Immun (1993) 1.49
Clinical implications of positive blood cultures. Clin Microbiol Rev (1989) 1.48
Biological properties of structurally related alpha-helical cationic antimicrobial peptides. Infect Immun (1999) 1.40
Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy. J Clin Invest (1992) 1.35
Cell-free pool of CD14 mediates activation of transcription factor NF-kappa B by lipopolysaccharide in human endothelial cells. Proc Natl Acad Sci U S A (1993) 1.32
False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products. J Clin Microbiol (1989) 1.24
Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci U S A (1998) 1.17
Immunoreactivity and bioactivity of lipopolysaccharide-binding protein in normal and heat-inactivated sera. Infect Immun (1995) 1.12
A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation. J Exp Med (1993) 1.12
Prolonged exposure of rat aorta to low levels of endotoxin in vitro results in impaired contractility. Association with vascular cytokine release. J Clin Invest (1990) 1.08
Rapid diagnosis of gram negative pneumonia by assay of endotoxin in bronchoalveolar lavage fluid. Thorax (1992) 1.02
Lack of correlation between failure of gut barrier function and septic complications after major upper gastrointestinal surgery. Ann Surg (2000) 0.98
Endotoxin levels in sera of elderly individuals. Clin Diagn Lab Immunol (1994) 0.97
Saturable CD14-dependent binding of fluorescein-labeled lipopolysaccharide to human monocytes. Infect Immun (1997) 0.96
Bench-to-bedside review: Clinical experience with the endotoxin activity assay. Crit Care (2012) 0.95
Microvascular permeability during experimental human endotoxemia: an open intervention study. Crit Care (2005) 0.94
Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins. Antimicrob Agents Chemother (1992) 0.92
Prolonged expression of lipopolysaccharide (LPS)-induced inflammatory genes in whole blood requires continual exposure to LPS. Infect Immun (1995) 0.91
A synthetic lipopolysaccharide-binding peptide based on the neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats. Infect Immun (1997) 0.90
APOε4 is associated with enhanced in vivo innate immune responses in human subjects. J Allergy Clin Immunol (2014) 0.90
Preoperative apolipoprotein CI levels correlate positively with the proinflammatory response in patients experiencing endotoxemia following elective cardiac surgery. Intensive Care Med (2008) 0.90
Concordance of endotoxemia with gram-negative bacteremia in patients with gram-negative sepsis: a meta-analysis. J Clin Microbiol (1994) 0.87
Reappraisal with meta-analysis of bacteremia, endotoxemia, and mortality in gram-negative sepsis. J Clin Microbiol (1995) 0.87
Impaired phagocyte responses to lipopolysaccharide in paroxysmal nocturnal hemoglobinuria. Infect Immun (1993) 0.86
An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan. Infect Immun (1993) 0.85
Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice. Infect Immun (1992) 0.84
Gene expression of interleukin 18 in unstimulated peripheral blood mononuclear cells of patients with alcoholic cirrhosis. Gut (2001) 0.84
Does gram-negative bacteraemia occur without endotoxaemia? A meta-analysis using hierarchical summary ROC curves. Eur J Clin Microbiol Infect Dis (2009) 0.84
The role of tumour necrosis factor in the kinetics of lipopolysaccharide-mediated neutrophil priming in whole blood. Clin Exp Immunol (2005) 0.83
Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome. Ann Surg (1993) 0.82
Increased concentrations of Serum amyloid A in dogs with sepsis caused by pyometra. BMC Vet Res (2014) 0.82
Specific detection of Haemophilus influenzae type b lipooligosaccharide by immunoassay. J Clin Microbiol (1990) 0.80
Diagnosis of endotoxemia with gram-negative bacteremia is bacterial species dependent: a meta-analysis of clinical studies. J Clin Microbiol (2009) 0.79
Mediators of multiple organ failure. Intensive Care Med (1990) 0.78
Endotoxemia as a diagnostic tool for patients with suspected bacteremia caused by gram-negative organisms: a meta-analysis of 4 decades of studies. J Clin Microbiol (2015) 0.77
Endotoxemia and mortality prediction in ICU and other settings: underlying risk and co-detection of gram negative bacteremia are confounders. Crit Care (2012) 0.77
The imbalance between coagulation and fibrinolysis is related to the severity of the illness and the prognosis in sepsis. Korean J Intern Med (1999) 0.76
The relationship between gut-derived bacteria and the development of the multiple organ dysfunction syndrome. J Anat (1996) 0.76
Management of generalized faecal peritonitis. J R Soc Med (1992) 0.75
Initial metabolic state and exercise-induced endotoxaemia are unrelated to gastrointestinal symptoms during exercise. J Sports Sci Med (2009) 0.75
Intensive care. Postgrad Med J (1993) 0.75
Pulmonary infiltrates during community acquired Gram-negative bacteremia: a retrospective single centre study. Scand J Trauma Resusc Emerg Med (2013) 0.75
Clinical immunology. Postgrad Med J (1991) 0.75
Immunotherapy in the management of sepsis. Postgrad Med J (1995) 0.75
Septicaemia after colonoscopy in patients with cirrhosis. Gut (1992) 0.75
[Endotoxins. Pathogenetic meaning of sepsis]. Anaesthesist (2003) 0.75
Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med (2009) 8.30
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 5.48
Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med (1992) 3.74
Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med (1997) 3.26
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Microparticles in cardiovascular diseases. Cardiovasc Res (2003) 2.62
Measuring circulating cell-derived microparticles. J Thromb Haemost (2004) 2.61
Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood (2000) 2.51
Prevention of Yersinia enterocolitica growth in red-blood-cell concentrates. Lancet (1992) 2.44
Single vs. swarm detection of microparticles and exosomes by flow cytometry. J Thromb Haemost (2012) 2.39
A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med (1993) 2.39
Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost (2001) 2.38
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 2.33
Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet (1997) 2.20
Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost (2010) 2.19
Limitations of compression ultrasound for the detection of symptomless postoperative deep vein thrombosis. Lancet (1994) 2.18
[Atherosclerosis partly due to local vasculitis]. Ned Tijdschr Geneeskd (1994) 2.05
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
[Optimal treatment with oral anticoagulants]. Ned Tijdschr Geneeskd (1996) 2.03
Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost (2014) 1.90
Value of myoglobin, troponin T, and CK-MBmass in ruling out an acute myocardial infarction in the emergency room. Circulation (1995) 1.82
Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation (1992) 1.78
Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med (1990) 1.76
Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet (1994) 1.76
Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest (2004) 1.74
Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis (1992) 1.73
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet (1992) 1.73
Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med (1996) 1.70
Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation (1997) 1.67
Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost (2001) 1.65
Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med (1999) 1.64
Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med (1994) 1.63
Reliable rapid blood test for the exclusion of venous thromboembolism in symptomatic outpatients. Thromb Haemost (1996) 1.61
The value of lung scintigraphy in the diagnosis of pulmonary embolism. Eur J Nucl Med (1993) 1.61
Intestinal endotoxemia. Clinical significance. Gastroenterology (1988) 1.59
Antigen biological activity ratio for factor VIII in late pregnancy. Lancet (1973) 1.54
Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med (1983) 1.51
Review: infectious diseases and coagulation disorders. J Infect Dis (1999) 1.50
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
Cell-derived microparticles contain caspase 3 in vitro and in vivo. J Thromb Haemost (2005) 1.45
Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost (2003) 1.41
Additive effect of dDAVP and standard heparin in increasing plasma t-PA. Thromb Haemost (1989) 1.39
[Deep venous thrombosis: does recently improved knowledge lead to a real advance in the direction patient care?]. Ned Tijdschr Geneeskd (1996) 1.39
[Cellular microparticles and blood-vessel damage. II. Functional characteristics and clinical significance]. Ned Tijdschr Geneeskd (2004) 1.38
[Antifibrinolytic therapy]. Ned Tijdschr Geneeskd (1995) 1.38
[Diagnostic management in suspicion of pulmonary embolism: results of a survey among Dutch internists and pulmonologists]. Ned Tijdschr Geneeskd (1992) 1.38
[High-density lipoproteins]. Ned Tijdschr Geneeskd (1992) 1.38
Failure of computerized impedance plethysmography in the diagnostic management of patients with clinically suspected deep-vein thrombosis. Thromb Haemost (1991) 1.32
A new computerized impedance plethysmograph: accuracy in the detection of proximal deep-vein thrombosis in symptomatic outpatients. Thromb Haemost (1991) 1.29
Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood (1994) 1.28
Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med (1992) 1.27
Genetic influence on cytokine production in meningococcal disease. Lancet (1997) 1.23
Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J Immunol (1997) 1.21
Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest (1989) 1.20
Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood (1992) 1.17
Relationship between intra-uterine bacterial contamination, endotoxin levels and the development of endometritis in postpartum cows with dystocia or retained placenta. Theriogenology (2000) 1.17
Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med (1998) 1.16
Relationship between gastro-intestinal complaints and endotoxaemia, cytokine release and the acute-phase reaction during and after a long-distance triathlon in highly trained men. Clin Sci (Lond) (2000) 1.15
The localization of factor V within normal human platelets and the demonstration of a platelet-factor V antigen in congenital factor V deficiency. Br J Haematol (1975) 1.15
Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. Arch Intern Med (2003) 1.13
Interleukin-6 mediates host defense responses induced by abdominal surgery. Surgery (1993) 1.13
Placental-type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol (1988) 1.13
Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis. A randomized trial. Ann Intern Med (1985) 1.11
Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med (1991) 1.11
Factor VIII deficiency does not protect against atherosclerosis. J Thromb Haemost (2012) 1.11
Phospholipid composition of cell-derived microparticles determined by one-dimensional high-performance thin-layer chromatography. Anal Biochem (2002) 1.11
Proinflammatory cytokines and elastase-alpha-1-antitrypsin in Argentine hemorrhagic fever. Am J Trop Med Hyg (1999) 1.10
Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo. J Thromb Haemost (2003) 1.09
Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost (1996) 1.09
[Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo]. Ned Tijdschr Geneeskd (1993) 1.08
Determination of tumour necrosis factor-alpha and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation. J Immunol Methods (1998) 1.08
Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis (1985) 1.07
Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood (1997) 1.06
Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis (1993) 1.05
Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol (1989) 1.05
Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch Intern Med (2000) 1.05
The clinical course of patients with suspected pulmonary embolism. Arch Intern Med (1998) 1.04
Intestinal permeability, circulating endotoxin, and postoperative systemic responses in cardiac surgery patients. J Cardiothorac Vasc Anesth (1996) 1.03
The phospholipid composition and cholesterol content of platelet-derived microparticles: a comparison with platelet membrane fractions. J Thromb Haemost (2005) 1.02
Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. N Engl J Med (1986) 1.02
Two consecutive high-fat meals affect endothelial-dependent vasodilation, oxidative stress and cellular microparticles in healthy men. J Thromb Haemost (2006) 1.02
Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. J Thromb Haemost (2006) 1.01
Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects. Thromb Haemost (1998) 1.01
Quantitative endotoxin determination in blood with a chromogenic substrate. Clin Chim Acta (1981) 1.01
The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost (1996) 1.01
Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients. J Clin Microbiol (2000) 0.98
Coagulopathy in Ruptured or Dissecting Aortic Aneurysms. Am J Med (1975) 0.98
Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem (1988) 0.98
Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood (1997) 0.97
Effect of hormonal manipulation on antithrombin III activity in patients with prostatic carcinoma. Eur Urol (1984) 0.97
Effect of O-(beta-hydroxyethyl)-rutoside on red cell and platelet functions in man. Bibl Anat (1973) 0.97
Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation (1993) 0.96
Detection and clinical relevance of human endotoxemia. Z Med Lab Diagn (1990) 0.96